Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Article

Efficacy and Safety of a Topical Botanical in Female Androgenetic Alopecia: A Randomized, Single-Blinded, Vehicle-Controlled Study

Katoulis A.C.a · Liakou A.I.a · Alevizou A.a · Bonovas S.b · Bozi E.a · Kontogiorgi D.a · Rigopoulos D.a

Author affiliations

a2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens Medical School, “Attikon” General University Hospital, Athens, Greece; bHumanitas Clinical and Research Center, Milan, Italy

Related Articles for ""

Skin Appendage Disord 2018;4:160-165

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: May 30, 2017
Accepted: August 03, 2017
Published online: November 16, 2017
Issue release date: Published online first

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 2

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD

Abstract

Introduction: Androgenetic alopecia (AGA) in females is a difficult to treat skin disorder. A novel topical botanical lotion has been approved for its treatment. It acts by increasing Bcl-2, perifollicular Langerhans and mast cells, and perifollicular collagen. The aim of this study was to evaluate the efficacy and safety of this lotion in females. Methods: Forty women with AGA were randomized to apply the active lotion or placebo, twice daily for 24 weeks. Subjects were evaluated at 0, 12, and 24 weeks by clinical examination, photographic documentation, quality of life evaluation (DLQI), and trichogram (anagen to telogen ratio). Results: The clinical evaluation demonstrated an increased hair density in the intervention group (great improvement in 7.7%, moderate in 88.5%, and stable in 3.8%). The self-assessment score increased from 4.5 to 6.0 (24 weeks), and the DLQI improved from 4 to 3 in the intervention group (p < 0.001). The mean anagen to telogen ratio in the intervention group was 2.1, 3.9, and 6.0 at 0, 12, and 24 weeks, respectively, whereas in the control group it was 2.2, 3.8, and 3.3, respectively. Conclusion: The new topical botanical lotion showed remarkable efficacy, with a high degree of patient satisfaction and improvement of their quality of life.

© 2017 S. Karger AG, Basel


References

  1. Rogers NE, Avram MR: Medical treatments for male and female pattern hair loss. J Am Acad Dermatol 2008;59:547-566.
  2. Blume-Peytavi U, et al: S1 guideline for diagnostic evaluation in androgenetic alopecia in men, women and adolescents. Br J Dermatol 2011;164:5-15.
  3. Blumeyer A, et al: Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011;9:1-57.
  4. Norwood O, Lehr B: Female androgenetic alopecia: a separate entity. Dermatol Surg 2000;26:679-682.
  5. Trüeb RM: Molecular mechanisms of androgenetic alopecia. Exp Gerontol 2002;37:981-990.
  6. Olsen EA: Female pattern hair loss. J Am Acad Dermatol 2002;45:70-80.
  7. Tosti A, Piraccini BM: Androgenetic alopecia; in Tosti A, Piraccini BM (eds): Diagnosis and Treatment of Hair Disorders: An Evidence Based Atlas. London, Taylor and Francis, 2006, pp 45-56.
  8. Yip L, Rufaut N, Sinclair R: Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol 2011;52:81-88.
  9. Arias-Santiago S, et al: Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 2010;63:420-429.
  10. Norwood OT: Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001;27:53-54.
  11. Birch MP, Messenger JF, Messenger AG: Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol 2001;144:297-304.
  12. Paik JH, Yoon JB, Sim WY, et al: The prevalence and types of androgenetic alopecia in Korean men and women. Br J Dermatol 2001;145:95-99.
  13. Price VH: Androgenetic alopecia in women. J Investig Dermatol Symp Proc 2003;8:24-27.
  14. Gan DCC, Sinclair RD: Prevalence of male and female pattern hair loss in Maryborough. J Investig Dermatol Symp Proc 2005;10:184-189.
  15. Xu F, Sheng YY, Mu Zl, et al: Prevalence and types of androgenetic alopecia in Shanghai, China: a community-based study. Br J Dermatol 2009;160:629-632.
  16. O'Tar T: Incidence of female androgenetic alopecia (female pattern alopecia). Dermatol Surg 2001;27:53-54.
  17. Lee AT, Zane LT: Dermatologic manifestations of polycystic ovary syndrome. Am J Clin Dermatol 2007;8:201-219.
  18. Bergfeld WF: Androgenetic alopecia: an autosomal dominant disorder. Am J Med 1995;98:95-98.
  19. Cash TF: The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992;26:926-931.
  20. Donk J, et al: Psychological characteristics of women with androgenetic alopecia: a controlled study. Br J Dermatol 1991;125:248-252.
  21. Venning VA, Dawber RPR: Patterned androgenic alopecia in women. J Am Acad Dermatol 1988;18:1073-1077.
    External Resources
  22. Cash TF, Price VH, Savin RC: Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol 1993;29:568-575.
  23. Olsen EA, Messenger AG, Shapiro J, et al: Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol 2005;52:301-311.
  24. DeVillez RL, et al: Androgenetic alopecia in the female: treatment with 2% topical minoxidil solution. Arch Dermatol 1994;130:303-307.
  25. Price VH, et al: Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am Acad Dermatol 2000;43:768-776.
  26. Vexiau P, et al: Effects of minoxidil 2% versus cyproterone acetate treatment on female androgenetic alopecia: a controlled, 12-month randomized trial. Br J Dermatol 2002;146:992-999.
  27. Whiting DA, Jacobson C: Treatment of female androgenetic alopecia with minoxidil 2%. Int J Dermatol 1992;31:800-804.
  28. Blume-Peytavi U, et al: A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65:1126-1134.
  29. Keaney TC, Pham H, von Grote E, Meckfessel MH: Efficacy and safety of minoxidil 5% foam in combination with a botanical hair solution in men with androgenic alopecia. J Drugs Dermatol 2016;15:406-412.
    External Resources
  30. McMichael A, Pham A, von Grote E, Meckfessel MH: Efficacy and safety of minoxidil 2% solution in combination with a botanical hair solution in women with female pattern hair loss/androgenic alopecia. J Drugs Dermatol 2016;15:398-404.
    External Resources
  31. Takeda A, Sato A, Zhang L, Harti S, Cauwenbergh G, et al: CG210 enables finasteride 1mg users to further improve hair pattern: a randomized, double-blind, placebo-controlled pilot study. Hair Ther Transplant 2013;3:107.
  32. Cucé LC, Rodrigues CJ, Patriota RCR: Cellium® GC: evaluation of a new natural active ingredient in 210 mg/mL topical solution, through scalp biopsy. Surg Cosmet Dermatol 2011;3:123-128.

Article / Publication Details

First-Page Preview
Abstract of Original Article

Received: May 30, 2017
Accepted: August 03, 2017
Published online: November 16, 2017
Issue release date: Published online first

Number of Print Pages: 6
Number of Figures: 1
Number of Tables: 2

ISSN: 2296-9195 (Print)
eISSN: 2296-9160 (Online)

For additional information: https://www.karger.com/SAD


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.